MX390786B - Métodos y composiciones para tratar somnolencia excesiva. - Google Patents
Métodos y composiciones para tratar somnolencia excesiva.Info
- Publication number
- MX390786B MX390786B MX2019014409A MX2019014409A MX390786B MX 390786 B MX390786 B MX 390786B MX 2019014409 A MX2019014409 A MX 2019014409A MX 2019014409 A MX2019014409 A MX 2019014409A MX 390786 B MX390786 B MX 390786B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- treating excessive
- excessive sleepiness
- sleepiness
- Prior art date
Links
- 208000032140 Sleepiness Diseases 0.000 title abstract 3
- 206010041349 Somnolence Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 230000037321 sleepiness Effects 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title 1
- 206010062519 Poor quality sleep Diseases 0.000 abstract 1
- NJVZDURTFWBXAM-VIFPVBQESA-N [(2S)-1-hydroxy-3-phenylpropan-2-yl]urea Chemical class C(N)(=O)N[C@@H](CC1=CC=CC=C1)CO NJVZDURTFWBXAM-VIFPVBQESA-N 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 201000003631 narcolepsy Diseases 0.000 abstract 1
- 208000001797 obstructive sleep apnea Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762514176P | 2017-06-02 | 2017-06-02 | |
| PCT/US2018/035532 WO2018222954A1 (en) | 2017-06-02 | 2018-06-01 | Methods and compositions for treating excessive sleepiness |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019014409A MX2019014409A (es) | 2022-03-17 |
| MX390786B true MX390786B (es) | 2025-03-21 |
Family
ID=64455104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019014409A MX390786B (es) | 2017-06-02 | 2018-06-01 | Métodos y composiciones para tratar somnolencia excesiva. |
Country Status (12)
| Country | Link |
|---|---|
| US (7) | US10959976B2 (enExample) |
| EP (1) | EP3630072A4 (enExample) |
| JP (1) | JP2020528075A (enExample) |
| KR (3) | KR20200016889A (enExample) |
| CN (1) | CN111201014A (enExample) |
| AU (1) | AU2018278332B2 (enExample) |
| BR (1) | BR112019025286A2 (enExample) |
| CA (1) | CA3065522A1 (enExample) |
| MX (1) | MX390786B (enExample) |
| MY (1) | MY203401A (enExample) |
| PH (1) | PH12019502723A1 (enExample) |
| WO (1) | WO2018222954A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US10195151B2 (en) | 2016-09-06 | 2019-02-05 | Jazz Pharmaceuticals International Iii Limited | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
| EP3630072A4 (en) | 2017-06-02 | 2021-03-10 | Jazz Pharmaceuticals Ireland Limited | METHODS AND COMPOSITIONS FOR TREATMENT OF EXCESSIVE Drowsiness |
| JP7553453B2 (ja) | 2019-03-01 | 2024-09-18 | フラメル アイルランド リミテッド | 食事摂取状態における改善された薬物動態を有するガンマ－ヒドロキシ酪酸塩組成物 |
| WO2021001457A1 (en) * | 2019-07-04 | 2021-01-07 | Sandoz Ag | Crystalline (r)-2-amino-3-phenylpropylcarbamate acid addition salts |
| US10940133B1 (en) | 2020-03-19 | 2021-03-09 | Jazz Pharmaceuticals Ireland Limited | Methods of providing solriamfetol therapy to subjects with impaired renal function |
| US20240358668A1 (en) * | 2021-09-03 | 2024-10-31 | Axsome Therapeutics, Inc. | Methods and compisitions for ameliorating biomarkers associated with cardiovascualr risk using (r)-2-amino-3-phenylpropyl carbamate |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| AU2023375326A1 (en) * | 2022-11-07 | 2025-05-22 | Axsome Therapeutics | Compositions and methods for treating insomnia |
| EP4626417A1 (en) * | 2022-11-30 | 2025-10-08 | Axsome Therapeutics | Methods and compositions for improving driving performance |
| US11771666B1 (en) | 2022-12-30 | 2023-10-03 | Axsome Malta Ltd. | Methods of administering solriamfetol to lactating women |
| US12005036B1 (en) | 2022-12-30 | 2024-06-11 | Axsome Malta Ltd. | Methods of administering solriamfetol to lactating women |
| CN120641090A (zh) * | 2022-12-30 | 2025-09-12 | 阿克苏姆马耳他有限公司 | 向哺乳期女性施用索安非托的方法 |
| US12102609B2 (en) | 2022-12-30 | 2024-10-01 | Axsome Malta Ltd. | Methods of administering solriamfetol to lactating women |
| US12036194B1 (en) | 2022-12-30 | 2024-07-16 | Axsome Malta Ltd. | Methods of administering solriamfetol to lactating women |
| US12064411B1 (en) * | 2022-12-30 | 2024-08-20 | Axsome Malta Ltd. | Methods of administering solriamfetol to lactating women |
| US12090126B2 (en) | 2022-12-30 | 2024-09-17 | Axsome Malta Ltd. | Methods of administering solriamfetol to lactating women |
| AU2024278948A1 (en) * | 2023-05-30 | 2025-12-11 | Axsome Therapeutics, Inc. | Solriamfetol for treating cognitive impairment in a subject with impaired cognition associated with obstructive sleep apnea and excessive daytime sleepiness |
| WO2025042959A1 (en) * | 2023-08-21 | 2025-02-27 | Axsome Therapeutics, Inc. | Use of solriamfetol for the treatment of orphan diseases |
| WO2025064549A1 (en) * | 2023-09-18 | 2025-03-27 | Axsome Therapeutics, Inc. | Solriamfetol for improving cognitive health in apnea patients |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2939660A1 (de) | 1979-09-29 | 1981-04-16 | Basf Ag, 6700 Ludwigshafen | Neue carbamate, ihre herstellung und diese enthaltende pharmazeutische zubereitungen |
| CZ285829B6 (cs) | 1993-06-10 | 1999-11-17 | Eli Lilly And Company | Použití derivátu tetrahydrobenz [c,d]indolu pro výrobu farmaceutického prostředku vhodného pro ošetřování sexuální dysfunkce |
| DE9311004U1 (de) | 1993-07-23 | 1993-10-14 | Mauser-Werke GmbH, 50321 Brühl | Palettencontainer |
| KR100197892B1 (ko) | 1994-09-09 | 1999-06-15 | 남창우 | 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법 |
| US5756817C1 (en) | 1995-02-11 | 2001-04-17 | Sk Corp | O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same |
| KR0173862B1 (ko) | 1995-02-11 | 1999-04-01 | 조규향 | O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| KR0173863B1 (ko) | 1995-04-10 | 1999-04-01 | 조규향 | 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| ES2170878T3 (es) | 1996-10-10 | 2002-08-16 | Sk Corp | Compuestos de o-carbamoil-fenilalaninol y sus sales farmaceuticamente utiles. |
| WO1998017636A1 (en) | 1996-10-22 | 1998-04-30 | Ortho Pharmaceutical Corporation | Phenylalaninol derivatives for the treatment of central nervous system disorders |
| CA2355293C (en) | 1998-12-23 | 2005-08-16 | Orphan Medical, Inc. | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
| US6680322B2 (en) | 1999-12-02 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| WO2002067921A1 (en) | 2001-02-27 | 2002-09-06 | Ortho-Mcneil Pharmaceutical, Inc. | Carbamate compounds for use in preventing or treating bipolar disorder |
| WO2002067926A1 (en) | 2001-02-27 | 2002-09-06 | Ortho-Mcneil Pharmaceutical, Inc. | Carbamate compounds for use in preventing or treating movement disorders |
| DK1399144T3 (da) | 2001-02-27 | 2006-07-24 | Ortho Mcneil Pharm Inc | Carbamatforbindelser til anvendelse ved forebyggelse eller behandling af angstforstyrrelser |
| US6680299B2 (en) | 2001-07-27 | 2004-01-20 | Enanta Pharmaceuticals, Inc. | 4'-substituted leucomycins |
| EP1534238A1 (en) | 2002-07-29 | 2005-06-01 | ALZA Corporation | Formulations and dosage forms for controlled delivery of topiramate |
| US20050080268A1 (en) | 2003-10-08 | 2005-04-14 | Yong-Moon Choi | Process of preparing O-carbamoyl compounds in the presence of active amine group |
| US20050203130A1 (en) | 2003-12-02 | 2005-09-15 | Erik Buntinx | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| CN101132787A (zh) | 2004-10-28 | 2008-02-27 | Sk株式会社 | 抑郁的辅助疗法 |
| CN101217949B (zh) | 2005-06-08 | 2012-10-17 | 爱思开生物制药株式会社 | 治疗睡眠-清醒病症 |
| DE602006012670D1 (de) | 2005-06-22 | 2010-04-15 | Sk Holdings Co Ltd | Behandlung der sexuellen dysfunktion |
| JP5094720B2 (ja) | 2005-07-26 | 2012-12-12 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | サブスタンス関連障害を処置する方法 |
| CA2673487A1 (en) | 2006-10-13 | 2008-04-24 | Janssen Pharmaceutica Nv | Phenylalkylamino carbamate compositions |
| US8778398B2 (en) | 2008-11-04 | 2014-07-15 | Jazz Pharmaceuticals, Inc. | Immediate release formulations and dosage forms of gamma-hydroxybutyrate |
| US8771735B2 (en) | 2008-11-04 | 2014-07-08 | Jazz Pharmaceuticals, Inc. | Immediate release dosage forms of sodium oxybate |
| CA2765463C (en) | 2009-06-22 | 2018-10-09 | Moise A. Khayrallah | Methods for treating or preventing fatigue |
| US8232315B2 (en) | 2009-06-26 | 2012-07-31 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating drug addiction and improving addiction-related behavior |
| ES2743153T3 (es) | 2009-11-06 | 2020-02-18 | Sk Biopharmaceuticals Co Ltd | Métodos para tratar el síndrome de fibromialgia |
| RU2556585C2 (ru) | 2009-11-06 | 2015-07-10 | Ск Биофармасъютиклс Ко., Лтд. | Способы лечения синдрома дефицита внимания и гиперактивности |
| WO2011139271A1 (en) | 2010-05-04 | 2011-11-10 | Jazz Pharmaceuticals, Inc. | Immediate release formulations and dosage forms of gamma-hydroxybutyrate |
| EP2392325A1 (en) | 2010-06-04 | 2011-12-07 | Universitätsklinikum Münster | Compounds for the prevention and/or treatment of osteoarthrosis |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| US9050302B2 (en) | 2013-03-01 | 2015-06-09 | Jazz Pharmaceuticals Ireland Limited | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
| DK2968208T3 (da) | 2013-03-13 | 2022-08-22 | Jazz Pharmaceuticals Ireland Ltd | Behandling af kataplexi |
| WO2015006685A1 (en) | 2013-07-12 | 2015-01-15 | Jazz Pharmaceuticals International Iii Limited | Promotion of smoking cessation |
| TW201919605A (zh) | 2013-07-18 | 2019-06-01 | 南韓商愛思開生物製藥股份有限公司 | 肥胖之治療 |
| TWI698415B (zh) | 2014-02-28 | 2020-07-11 | 南韓商愛思開生物製藥股份有限公司 | 胺基羰基胺基甲酸酯化合物 |
| US10195151B2 (en) | 2016-09-06 | 2019-02-05 | Jazz Pharmaceuticals International Iii Limited | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
| EP3630072A4 (en) | 2017-06-02 | 2021-03-10 | Jazz Pharmaceuticals Ireland Limited | METHODS AND COMPOSITIONS FOR TREATMENT OF EXCESSIVE Drowsiness |
| US10940133B1 (en) | 2020-03-19 | 2021-03-09 | Jazz Pharmaceuticals Ireland Limited | Methods of providing solriamfetol therapy to subjects with impaired renal function |
-
2018
- 2018-06-01 EP EP18810236.2A patent/EP3630072A4/en active Pending
- 2018-06-01 MY MYPI2019007118A patent/MY203401A/en unknown
- 2018-06-01 US US16/618,735 patent/US10959976B2/en active Active
- 2018-06-01 JP JP2020516785A patent/JP2020528075A/ja active Pending
- 2018-06-01 MX MX2019014409A patent/MX390786B/es unknown
- 2018-06-01 CA CA3065522A patent/CA3065522A1/en active Pending
- 2018-06-01 KR KR1020197038348A patent/KR20200016889A/ko not_active Ceased
- 2018-06-01 KR KR1020247036596A patent/KR20240162165A/ko active Pending
- 2018-06-01 WO PCT/US2018/035532 patent/WO2018222954A1/en not_active Ceased
- 2018-06-01 CN CN201880049345.2A patent/CN111201014A/zh active Pending
- 2018-06-01 KR KR1020237033870A patent/KR102726728B1/ko active Active
- 2018-06-01 BR BR112019025286-0A patent/BR112019025286A2/pt not_active Application Discontinuation
- 2018-06-01 AU AU2018278332A patent/AU2018278332B2/en active Active
-
2019
- 2019-12-02 PH PH12019502723A patent/PH12019502723A1/en unknown
-
2020
- 2020-05-19 US US16/877,717 patent/US10912754B2/en active Active
-
2021
- 2021-03-25 US US17/212,079 patent/US11648232B2/en active Active
-
2023
- 2023-05-12 US US18/316,841 patent/US11865098B1/en active Active
- 2023-12-08 US US18/534,234 patent/US20240180866A1/en not_active Abandoned
-
2024
- 2024-02-20 US US18/582,125 patent/US20240189270A1/en not_active Abandoned
- 2024-12-17 US US18/983,605 patent/US20250114322A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019025286A2 (pt) | 2020-06-23 |
| US10912754B2 (en) | 2021-02-09 |
| JP2020528075A (ja) | 2020-09-17 |
| EP3630072A1 (en) | 2020-04-08 |
| PH12019502723A1 (en) | 2020-07-13 |
| US10959976B2 (en) | 2021-03-30 |
| CN111201014A (zh) | 2020-05-26 |
| US20250114322A1 (en) | 2025-04-10 |
| MY203401A (en) | 2024-06-26 |
| US20210205257A1 (en) | 2021-07-08 |
| AU2018278332B2 (en) | 2022-05-19 |
| WO2018222954A1 (en) | 2018-12-06 |
| US20240189270A1 (en) | 2024-06-13 |
| CA3065522A1 (en) | 2018-12-06 |
| EP3630072A4 (en) | 2021-03-10 |
| US20200281886A1 (en) | 2020-09-10 |
| US11648232B2 (en) | 2023-05-16 |
| KR20200016889A (ko) | 2020-02-17 |
| AU2018278332A1 (en) | 2020-01-30 |
| MX2019014409A (es) | 2022-03-17 |
| US20200163927A1 (en) | 2020-05-28 |
| KR20230145525A (ko) | 2023-10-17 |
| KR20240162165A (ko) | 2024-11-14 |
| US11865098B1 (en) | 2024-01-09 |
| US20240033243A1 (en) | 2024-02-01 |
| NZ760594A (en) | 2025-05-02 |
| KR102726728B1 (ko) | 2024-11-05 |
| US20240180866A1 (en) | 2024-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX390786B (es) | Métodos y composiciones para tratar somnolencia excesiva. | |
| CY1123367T1 (el) | Μεθοδοι και συνθεσεις για τη ρυθμιση της εκφρασης της απολιποπρωτεϊνης (α) | |
| EA201591743A1 (ru) | СТИМУЛЯТОРЫ sGC | |
| SA521422063B1 (ar) | تركيبات وطرق لتعديل نشاط ديهيدروجيناز بسلسلة قصيرة | |
| MX388693B (es) | Composiciones de nanoparticulas para terapia sostenida. | |
| BR112017026739A2 (pt) | compostos para uso no tratamento de distúrbios neuromusculares | |
| CL2021002681A1 (es) | Inhibidores de la dihidroorotato deshidrogenasa. | |
| EA201791747A1 (ru) | 3-алкил-4-амидобициклические [4,5,0] гидроксамовые кислоты в качестве ингибиторов hdac | |
| UY30097A1 (es) | Usos terapeuticos de inhibidores de rtp801 | |
| PH12017501611A1 (en) | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof | |
| MA40240A (fr) | Composés hétéroaryle d'inhibition de la kinase | |
| SA520411187B1 (ar) | نظائر فينيل ألانينول كربامويل واستخداماتها | |
| MX379318B (es) | Metodos para tratar trastornos de sueño de ritmo circadiano. | |
| CL2022003348A1 (es) | Composiciones y métodos para el tratamiento del síndrome de dificultad respiratoria aguda y trastornos inflamatorios | |
| BR112015026021A2 (pt) | terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer | |
| BR112022004576A2 (pt) | Métodos para diminuir ou tratar sonolência excessiva, tratar narcolepsia tipo 2 ou hipersonia idiopática, tratar distúrbio de trabalho de turno, aumentar latência de sono em manutenção de teste de insônia, melhorar classificação de escaça de sonolência de karolinska, diminuir ou melhorar sonolência subjetiva, aumentar insônia ou diminuir sonolência excessiva, melhorar classificação de escala de sonolência epworth, tratar narcolepsia tipo 2, diminuir ou tratar sonolência diurna excessiva, e, composição farmacêutica | |
| PH12019500751A1 (en) | Carbamoyl phenylalaninol compounds and uses thereof | |
| MX2021006463A (es) | Metodos para el tratamiento de trastornos de expansion repetida de trinucleotidos asociados con actividad msh3. | |
| EP4345110A3 (en) | Methods for treating severe atopic dermatitis by administering an il-4r inhibitor | |
| GEP20247644B (en) | Inhibitors of adrenoreceptor adrac2 | |
| MX2015009696A (es) | Composiciones estables que comprenden heparinoide, anestesico de accion aguda y regulador de ph. | |
| EP4279127A3 (en) | Growth differentiation factor 15 as biomarker for metformin | |
| JOP20200291A1 (ar) | معدلات التعبير عن apol1 | |
| WO2014116556A3 (en) | Compositions and methods for regulating thermogenesis and muscle inflammation using metrnl and metrn | |
| MX2022007285A (es) | Compuestos, polimeros, dispositivos y usos de los mismos. |